Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPMPA ((1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid) is a synthetic small molecule that acts as a selective and competitive antagonist of GABA_A-rho receptors (previously known as GABA_C receptors). These receptors are primarily found in the retina but are also present in other tissues such as the hippocampus and spinal cord. TPMPA displays high selectivity for human recombinant ρ1 over ρ2 subtypes and has minimal effects on classical GABA_A or GABA_B receptors. It is used mainly as a pharmacological tool to investigate the function of GABA_A-rho receptors in neurophysiological research[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TPMPA.